Literature DB >> 12168068

The intraductal component of breast cancer is poorly responsive to neo-adjuvant chemotherapy.

Wenwen Wu1, Hiroshi Kamma, El Ueno, Masachika Fujiwara, Hiroaki Satoh, Hisato Hara, Tohru Yashiro, Yuji Aiyoshi.   

Abstract

Neo-adjuvant chemotherapy has been used for locally advanced breast cancers. With special attention to the proportion of intraductal component, we pathologically studied 25 patients that underwent neo-adjuvant chemotherapy via intra-arterial infusion or intravenous injection. In general, neo-adjuvant chemotherapy had a favorable effect on tumor reduction. The effectiveness varies depending on the predominance of intraductal component. The cases with a high proportion of intraductal component had lower response to the chemotherapies. The larger number of cancer cells remained within the mammary ducts. The residual cancer cells conserved proliferative activity. Intraductal component is poorly responsive to neoadjuvant chemotherapy.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12168068

Source DB:  PubMed          Journal:  Oncol Rep        ISSN： 1021-335X            Impact factor:   3.906


  5 in total

1.  Expression of heterogeneous nuclear ribonucleoproteins A2 and b1 in the thyroid follicular cells.

Authors:  Yukiko Yano; Wenwen Wu; Hiroshi Kamma; Masachika Fujiwara; Hisato Hara; Tohru Yashiro; Ei Ueno; Masanao Miwa; Yuji Aiyoshi
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

2.  Detection of intraductal component around invasive breast cancer using ultrasound: correlation with MRI and histopathological findings.

Authors:  Sangeetha Sundararajan; Eriko Tohno; Hiroshi Kamma; Ei Ueno; Manabu Minami
Journal:  Radiat Med       Date:  2006-02

3.  Pathologic Complete Response of HER-2 Neu-Positive Invasive Ductal Carcinoma and Ductal Carcinoma In Situ following Neoadjuvant Chemotherapy plus Trastuzumab: A Case Report and Review of Literature.

Authors:  Sommer R Gunia; Mita S Patel; Eleftherios P Mamounas
Journal:  Case Rep Surg       Date:  2012-01-19

4.  Pathological complete response (pCR) with or without the residual intraductal carcinoma component following preoperative treatment for pancreatic cancer: Revisiting the definition of "pCR" from the prognostic standpoint.

Authors:  Daisaku Yamada; Hidenori Takahashi; Kei Asukai; Shinichiro Hasegawa; Akira Tomokuni; Hiroshi Wada; Hirofumi Akita; Masayohi Yasui; Hiroshi Miyata; Osamu Ishikawa
Journal:  Ann Gastroenterol Surg       Date:  2019-09-20

5.  Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer.

Authors:  Emma J Groen; Marieke E M van der Noordaa; Frederieke H van Duijnhoven; Jelle Wesseling; Michael Schaapveld; Gabe S Sonke; Ritse M Mann; Mette S van Ramshorst; Esther H Lips; Marie-Jeanne T F D Vrancken Peeters
Journal:  Breast Cancer Res Treat       Date:  2021-05-04       Impact factor: 4.872
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.